Corneal opacity

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

KeraLink International Unveils Groundbreaking Strategy to Eradicate Corneal Blindness

Retrieved on: 
Monday, August 28, 2023

KeraLink International (KLI), a globally renowned charitable organization and leader in corneal health innovation, today unveiled three major initiatives to eradicate corneal blindness in low- and middle-income countries (LMICs): supporting the development of a groundbreaking approach to corneal regeneration; advancing a wholistic global strategy for preventing and treating corneal conditions that may lead to blindness; and spearheading a collaborative international effort to combat infectious keratitis, the leading cause of corneal blindness globally.

Key Points: 
  • KeraLink International (KLI), a globally renowned charitable organization and leader in corneal health innovation, today unveiled three major initiatives to eradicate corneal blindness in low- and middle-income countries (LMICs): supporting the development of a groundbreaking approach to corneal regeneration; advancing a wholistic global strategy for preventing and treating corneal conditions that may lead to blindness; and spearheading a collaborative international effort to combat infectious keratitis, the leading cause of corneal blindness globally.
  • “KeraLink International is unique in our singular focus on bringing health care providers, technology innovators, philanthropists, and investors into a coordinated, collaborative effort to eliminate corneal blindness in LMICs,” said Douglas J. Furlong, Board Chairman, KLI.
  • In the U.S., untreated corneal blindness is essentially a condition of the past.
  • Corneal blindness affects 12.7 million children and adults and threatens tens of millions more, even though it is preventable, treatable, and reversible.

Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness

Retrieved on: 
Tuesday, May 16, 2023

SUZHOU, China and SAN FRANCISCO, May 16, 2023 /PRNewswire/ -- Eluminex Biosciences (Eluminex) announced that its clinical pivotal study (CLARITY) evaluating a novel biosynthetic corneal implant (EB-301) currently being conducted in China was recognized for its groundbreaking work at two recent international ophthalmology meetings held in the United States.

Key Points: 
  • Eluminex's poster presentation entitled "A novel recombinant human collagen III (rhCIII) biosynthetic cornea (EB-301) to treat corneal blindness: initial results of the CLARITY Study" (poster 88312) presented on May 7, 2023, received honorable mention recognition in the category of Cornea.
  • The ASCRS annual meeting is an internationally recognized scientific symposium for clinicians and researchers in the field of cataract, refractive, cornea and glaucoma surgery.
  • The EB-301 investigational corneal implant is manufactured from recombinant human Type III collagen (rhCIII) and is intended to treat corneal blindness secondary to stromal lesions amenable to anterior lamellar keratoplasty (ALK) surgery as an alternative to human cadaveric corneal transplants.
  • Corneal blindness is a leading cause of vision loss globally; however, it is estimated that over half the world's population has no access to a corneal transplant.

Eyedea Medical awarded competitive National Science Foundation Phase II Small Business Innovation Research Grant, Baltimore, MD

Retrieved on: 
Thursday, February 23, 2023

BALTIMORE, Feb. 23, 2023 /PRNewswire/ -- Eyedea Medical, a Baltimore-based medtech startup working to alleviate the burden of corneal blindness through innovative solutions in corneal transplantation and eye banking, has been awarded a $1,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF).

Key Points: 
  • BALTIMORE, Feb. 23, 2023 /PRNewswire/ -- Eyedea Medical, a Baltimore-based medtech startup working to alleviate the burden of corneal blindness through innovative solutions in corneal transplantation and eye banking, has been awarded a $1,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF).
  • Our team believes access to vision care is a human right, and we founded Eyedea Medical to create technologies to help eliminate avoidable blindness.
  • The Phase II award validates our core technology platform and its potential to have a tangible impact on eye care," said Katie Solley, co-founder and CEO of Eyedea Medical.
  • The Phase II award builds off of a previous $225,000 NSF Phase I grant to de-risk the development of Eyedea Medical's first product, DescePrep™.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Wednesday, September 28, 2022

The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.

Key Points: 
  • The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.
  • All educational content of the AAO Annual Meeting is planned by its program committee, and AAO does not endorse, promote, approve or recommend the use of any products, devices or services.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof.

Global Ophthalmoscopes Market Report (2022 to 2027) - Key Players Include Heine USA, Dino Lite Europe, Iridex and Halma - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022

The "Ophthalmoscopes Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ophthalmoscopes Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of eye diseases is driving the growth of the eye testing equipment market.
  • Around 596 million people are suffering from distance vision impairment globally, of which 43 million people are blind.
  • Manufacturers' enhanced efforts to promote awareness about developments in ophthalmoscope technology are driving the global ophthalmoscopes market expansion.

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Retrieved on: 
Sunday, May 1, 2022

ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements in patients with various persistent corneal epithelial defect (PCED) etiologies, with complete healing of the PCED in six of eight evaluable patients. The data will be presented on Tuesday, May 3 in a poster session at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

Key Points: 
  • The data will be presented on Tuesday, May 3 in a poster session at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
  • PCED is a disease of impaired corneal healing which, if left untreated, can lead to infection, corneal perforation and irreversible vision loss.
  • Based on these early data, I believe KPI-012 could become the first treatment to address PCED across all etiologies and I look forward to further evaluating its potential in later-stage studies.
  • Healing after corneal injury follows a highly coordinated process involving growth factors, cell signaling, proliferation, migration and extracellular matrix remodeling.

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

Retrieved on: 
Tuesday, March 29, 2022

The designation covers both partial LCAT deficiency, presenting as Fisheye Disease, and complete LCAT deficiency presenting with renal symptoms and corneal opacities.

Key Points: 
  • The designation covers both partial LCAT deficiency, presenting as Fisheye Disease, and complete LCAT deficiency presenting with renal symptoms and corneal opacities.
  • Progression of LCAT deficiency, for which there is no approved treatment, can ultimately lead to renal failure requiring dialysis or kidney transplant, and/or to complete corneal opacification requiring transplant.
  • The European Medicines Administration (EMA) granted ODD status to CER-001 for the treatment of LCATdeficiency in July 2021.
  • Positive clinical results from CER-001 in LCAT disease have previously been published.

The Worldwide Corneal Transplantation Industry is Expected to Reach $640 Million by 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022

The corneal transplantation market is projected to reach $640.79 million by 2028 from $420.71 million in 2021; it is estimated to grow at a CAGR of 6.2% during 2021-2028.

Key Points: 
  • The corneal transplantation market is projected to reach $640.79 million by 2028 from $420.71 million in 2021; it is estimated to grow at a CAGR of 6.2% during 2021-2028.
  • However, the risks associated with Corneal Transplantation and shortage of donor material hampers the market growth.
  • Corneal blindness has complex epidemiology that includes a broad spectrum of infectious and inflammatory eye diseases causing corneal scars that contribute to functional blindness.
  • Trachoma, corneal ulcers, ophthalmia neonatorum, xerophthalmia, viral infections, onchocerciasis, leprosy, traditional eye medications, and eye injuries lead to corneal blindness.

Global Intraocular Lens Market to 2026 - Insight, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 8, 2021

Increasing prevalence of eye diseases such as refractive error, age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma is a major driver of the intraocular lens market in particular.

Key Points: 
  • Increasing prevalence of eye diseases such as refractive error, age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma is a major driver of the intraocular lens market in particular.
  • Another contributing factor that may be responsible for the growth of the intraocular lens market is the technological advancements in the development of IOLs.
  • Key companies dominating the Global Intraocular Lens Market.
  • Which are the regions and countries where companies should have concentrated on opportunities for intraocular lenses market growth in the coming future?